Yet, the treatment effect in the current study was only moderate and temporary, and the findings need further examination to elucidate the possible role of TLR4 in ALS, as well as the optimal dosing of TAK-242. The gene discussed is TLR4; the disease is amyotrophic lateral sclerosis.